Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
NCT00729924Phase 3Completed
- Sponsor
- Vanderbilt University
- Start
- Aug 2008
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Vanderbilt University. Started Aug 2008; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00729924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00729924.